Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656969 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2MGLL | |
| SCHEMBL4396319 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2WEE1 | |
| SCHEMBL85663 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2WEE1 | |
| SCHEMBL655077 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3MAPKAPK2WEE1 | |
| Hydrochloric Acid SCHEMBL1583516 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAPT | |
| SCHEMBL1584076 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MAPKAPK2MGLL | |
| SCHEMBL8286227 | 0.82 | ADRB1 (0.52) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAPT | |
| SCHEMBL532873 | 0.81 | NPC1 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2PTGS2 | |
| Hydrochloric Acid SCHEMBL1583739 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2MGLL | |
| Hydrochloric Acid SCHEMBL3657338 | 0.81 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3MAPKAPK2WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014026125-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | WO | disclosed |
| EP-2242746-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009098000-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009050236-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SLC6A2 4345/4885SLC6A4 3975/4885SLC6A3 4076/4885 |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SLC6A2 4345/4885SLC6A4 3975/4885SLC6A3 4076/4885 |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SLC6A2 4345/4885SLC6A4 3975/4885SLC6A3 4076/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | SLC6A2 4100/4885SLC6A4 4304/4885SLC6A3 4079/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | SLC6A2 4100/4885SLC6A4 4304/4885SLC6A3 4079/4885 |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | SLC6A2 4844/4885SLC6A4 4760/4885SLC6A3 4613/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | SLC6A2 4100/4885SLC6A4 4304/4885SLC6A3 4079/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SLC6A2 4345/4885SLC6A4 3975/4885SLC6A3 4076/4885 |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | SLC6A2 4844/4885SLC6A4 4760/4885SLC6A3 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.